What Coologics does

Coologics is a clinical-stage medical device company founded in 2019 and headquartered in Broadview Heights, Ohio (Cleveland metro area). The company is developing Vlisse, a single investigational product consisting of a patented, drug-free intravaginal cooling device designed as a tampon-like device to manage vaginal yeast infections by providing rapid symptom relief and clinical cure without antibiotics or drug-related side effects. The device uses proprietary controlled-cooling technology, with published peer-reviewed pilot study data in human and mouse models demonstrating safety and early potential efficacy.

The business model is pre-revenue and centered on regulatory clearance as the gating milestone. Vlisse is pursuing FDA De Novo Class II clearance in the United States and holds Class I device status with a pending CE Mark in the European Union. Upon clearance, the company intends to commercialize through healthcare provider channels (OB/GYNs, women's health clinics) and pharmacy distribution via prescription, operating a B2B2C model. The company has raised just over $3 million in seed funding (April 2025) led by Prevail Partners and Dream Ventures, with participation from Illini Angels and Ohio State Early Investor Network, earmarked for clinical trial completion, FDA submission, and market release.

Coologics is founder-led by Kim Langdon, MD, a practicing OB/GYN who is both a recurrent sufferer of vaginal infections and a preterm birth survivor, serving as CEO, Founder, and Inventor. Nicole Williams, MD serves as Chief Medical Officer. The company has 1-10 employees and operates in the women's health segment, positioning Vlisse against the antibiotic-resistance problem and the link between untreated vaginal infections and preterm births, citing a $14 billion productivity loss attributable to recurrent vaginal infections annually.

Name

Coologics

Legal name

Coologics

Website

https://coologics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Coologics is a clinical-stage medical device company developing Vlisse, a patented drug-free intravaginal cooling device for treating vaginal yeast infections. The Cleveland-based firm is pursuing FDA De Novo Class II clearance and serves OB/GYNs and women seeking antibiotic-free treatment options.

Ownership category

akta.pro rank

Product category

Women's Health Medical Devices

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK)

Keywords

• Drug-free medical devices
• Vaginal health devices
• Intravaginal cooling technology
• Women's health therapeutics
• Clinical stage devices

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Pre-revenue clinical-stage company developing Vlisse, a drug-free medical device for vaginal yeast infections. Once FDA cleared, the company will generate revenue through sales of its Class II medical device, likely through healthcare provider and pharmacy distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Coologics is developing Vlisse, a single drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. The device is currently in clinical trials and pursuing FDA De Novo Class II clearance in the U.S. and a CE Mark in the EU, with eventual commercial distribution planned through OB/GYNs, women's health clinics, and pharmacies.

Product overview

Coologics offers a single product (Vlisse) - a drug-free investigational medical device using patented controlled-cooling technology for treating vaginal yeast and bacterial infections. The tampon-like device is designed to provide rapid drug-free symptom relief and clinical cure without antibiotic-related side effects. The product is being developed as a De Novo Class II medical device in the US and is classified as a Class I Device in the European Union with CE Mark pending.

Differentiator

Problem solved

Functional benefit

Brands

• Vlisse: Drug-free investigational device for managing vaginal yeast infections using controlled-cooling technology, pursuing FDA clearance as a De Novo Class II medical device.

Products and services

• Vlisse Vlisse is a drug-free, tampon-like investigational medical device that uses patented controlled-cooling technology to provide rapid symptom relief and clinical cure for vaginal yeast infections without antibiotics. It is intended for prescription or clinical use by OB/GYNs and women's health providers, targeting women seeking a non-pharmaceutical alternative to traditional antifungal therapies.

Quantifiable outcome

• Published peer-reviewed pilot study demonstrates early potential to relieve symptoms and provide clinical cure
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Femasys: Clinical-stage women's health medical device company developing in-office reproductive health solutions, with a comparable pre-commercial regulatory profile and OB/GYN-focused commercialization pathway similar to Coologics' Vlisse.
• Minerva Surgical: Women's health medical device company commercializing devices for gynecological conditions; comparable in targeting the OB/GYN channel and pursuing FDA-cleared device solutions for underserved women's health indications.
• TherapeuticsMD: Women's health-focused company developing and commercializing prescription products in OB/GYN; comparable in concentrating on differentiated women's health interventions despite pharma (not device) modality.
• Daré Bioscience: Clinical-stage women's health biopharmaceutical/medical device company advancing novel therapies for women's reproductive and sexual health; comparable in clinical-stage profile and women's-health-only focus.

Broad incumbents

• CooperSurgical: Large established women's health medical device and diagnostics company serving OB/GYNs and reproductive health markets; comparable as a broad incumbent with overlapping distribution channels and clinician relationships that Vlisse will eventually need to access.
• Hologic: Major women's health diagnostics and medical device company with deep OB/GYN commercial reach; comparable as a broad incumbent whose scale and clinician relationships shape the competitive backdrop for any women's health device launch.
• Myriad Genetics: Women's health diagnostics company with hereditary cancer and reproductive health testing; comparable as a broad incumbent working with OB/GYNs to inform clinical decisions across reproductive and gynecologic care.
• Organon: Global women's health pharmaceutical company spun out of Merck with a portfolio spanning contraception, fertility, and gynecologic conditions; comparable as a broad incumbent addressing the same patient population via alternative therapeutic modalities.

Others

• Bayer: Diversified life sciences company with a substantial women's health franchise (contraception, gynecologic therapies); adjacent incumbent with overlapping therapeutic categories and global OB/GYN commercial footprint relevant to Vlisse's eventual market.

Emerging players

• Elidah: Early-commercial women's health medical device company (Elitone for stress urinary incontinence); comparable as a small, OB/GYN-adjacent medical device startup pursuing FDA-cleared, drug-free solutions for women's health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coologics